MMP-2、MMP-9及其抑制剂TIMP-2、TIMP-1与肾脏疾病

被引：2
|
作者：
童桂霞 [1 ]
胡晓晶 [2 ]
柳方娥 [1 ]
机构：
[1] 山东大学第二医院儿内科
[2] 青岛市立医院东院儿内科
来源：
国际儿科学杂志 | 2011年 / 04期
关键词：
基质金属蛋白酶; 金属蛋白酶组织抑制因子; 肾脏;
D O I：
暂无
中图分类号：
R725.9 [小儿全身性疾病];
学科分类号：
100202 ;
摘要：
肾脏细胞外基质(ECM)合成与降解失衡及其组织重塑导致的ECM积聚,是各种肾脏疾病发展至肾间质纤维化与肾小球硬化乃至终末期肾衰的共同病理表现。基质金属蛋白酶(MMP)是肾脏ECM降解的关键酶,金属蛋白酶组织抑制因子(TIMP)-2、-1分别为MMP-2、MMP-9内源性抑制剂。在不同类型的肾脏疾病或同一疾病的不同病理发展阶段,MMP/TIMP表达和(或)活性不同。该文就MMP-2、MMP-9及其抑制剂TIMP-2、TIMP-1的表达与肾脏疾病的关系作一综述。
引用
收藏
页码：416 / 419
相关论文
共 10 条
  • [1] SIGNIFICANCE OF MMP-2 AND TIMP-2 mRNA EXPRESSIONS ON GLOMERULAR CELLS IN THE DEVELOPMENT OF GLOMERULOSCLEROSIS
    Zhi-gang Zhang
    [J]. Chinese Medical Sciences Journal, 2004, (02) : 84 - 88
  • [2] Relationships between MMP-2, MMP-9, TIMP-1 and TIMP-2 levels and their pathogenesis in patients with lupus nephritis[J] . Zhongxin Jiang,Tao Sui,Bin Wang.Rheumatology International . 2010 (9)
  • [3] Role of angiotensin II, endothelin-1 and L-type calcium channel in the development of glomerular, tubulointerstitial and perivascular fibrosis[J] . Teresa M Seccia,Carmen Maniero,Anna S Belloni,Diego Guidolin,Poulose Pothen,Achille C Pessina,Gian Paolo Rossi.Journal of Hypertension . 2008 (10)
  • [4] Matrix metalloproteinase-2, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in the peripheral blood of patients with various glomerular diseases and their implication in pathogenetic lesions: study based on an enzyme-linked assay and immunohistochemical staining[J] . Tetsuya Endo,Kimimasa Nakabayashi,Makiho Sekiuchi,Tadahide Kuroda,Akinori Soejima,Akira Yamada.Clinical and Experimental Nephrology . 2006 (4)
  • [5] In situ gene expression and localization of metalloproteinases MMP1,MMP2, MMP3, MMP9, and their inhibitors TIMP1 and TIMP2 in human renal cell carcinoma[J] . Venugopal Bhuvarahamurthy,Glen Kristiansen,Manfred Johannsen,Stefan Loening,Dietmar Schnorr,Klaus Jung,Andrea Staack.Oncology Reports . 2006 (5)
  • [6] Decreased collagen-degrading activity could be a marker of prolonged mesangial matrix expansion
    Tomita M.
    Koike H.
    Han G.D.
    Shimizu F.
    Kawachi H.
    [J]. Journal of Clinical and Experimental Nephrology, 2004, 8 (1): : 17 - 26
  • [7] Matrix Metalloproteinase Activity in Urine of Patients with Renal Cell Carcinoma Leads to Degradation of Extracellular Matrix proteins: possible use as a Screening Assay[J] . MAHMOUD H. SHERIEF,SENG HUI LOW,MASUMI MIURA,NORIKO KUDO,ANDREW C. NOVICK,THOMAS WEIMBS.The Journal of Urology . 2003 (4)
  • [8] Cellular and molecular events leading to renal tubulointerstitial fibrosis
    Razzaque M.S.
    Taguchi T.
    [J]. Medical Electron Microscopy, 2002, 35 (2): : 68 - 80
  • [9] Specific changes in plasmaconcentrations of matrix metalloproteinase-2 and-9,TIMP-1and TGF-beta1 in patients with distinct types of primaryglomerulonephritis .2 Bauvois B,Mothu N,Nguyen J,et al. Nephrol Dial Transplant . 2007
  • [10] Elevation of serum levels of metalloproteinase-1, tissue inhibitor of metalloproteinase-1 and type Ⅳ collagen, and plasma levels of metalloproteinase-9 in polycystic kidney disease .2 Nakamura T,Ushiyama C,Suzuki S,et al. American Journal of Nephrology . 2000
1